DSM completes acquisition of Glycom
DSM’s acquisition of Glycom is designed to increase its leadership in the early life nutrition and dietary supplement space with its portfolio of nutritional lipids, vitamins and custom nutrient premixes.
HMOs are the third largest solid component of human milk after fat and lactose. Naturally occurring in human breast milk, they have evolved over thousands of years, providing us with unique health benefits. In particular, they support both immune and cognitive development.
There is significant interest in HMO use as a dietary supplement and potentially in food & beverage and pet food applications, and in fulfilling unmet medical nutrition needs, such as irritable bowel syndrome.
Glycom is a pioneer in HMOs, with a rich, science-backed product pipeline, and as the only one, a fully integrated HMO production facility in the world. It has its own product development, preclinical and clinical programs, regulatory team, as well as large-scale production in its state-of-the-art manufacturing plant in Esbjerg (Denmark).
Next-generation HMOs are part of Glycom’s exciting innovation roadmap, with four new HMOs becoming available this year to further catalyse the already fast-growing HMO market.